N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 14.82 CNY -0.74%
Market Cap: 23.9B CNY
Have any thoughts about
Nanjing King-friend Biochemical Pharmaceutical Co Ltd?
Write Note

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Income from Continuing Operations
-ÂĄ408.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
ÂĄ4.5B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-408.9m CNY

Based on the financial report for Jun 30, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Income from Continuing Operations amounts to -408.9m CNY.

Back to Top